Perspective Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Perspective Therapeutics (NYSE AMERICAN: CATX) said senior leadership will participate in investor events in April 2026. Key appearances include a presentation and fireside chat at the Needham Virtual Healthcare Conference on April 14, 2026 (9:30–10:10 a.m. ET) and one-on-one meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston.

Management will be available for investor 1x1 meetings; times and virtual access details follow each conference schedule.

News Market Reaction – CATX

-0.23%

-0.23% Session close to close

In the Apr 2 session, CATX declined 0.23%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:

25th Annual Needham Virtual Healthcare Conference – Presentation & Fireside Chat
Date: Tuesday, April 14, 2026
Time: 9:30-10:10 a.m. ET
Location: Virtual

Piper Sandler Spring Biopharma Symposium – 1x1s only
Date: Thursday, April 16, 2026
Location: Boston, MA

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary ²¹²Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s expectations regarding its interactions with regulatory agencies and the expected timing thereof; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contact:

Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

FAQ

When will Perspective Therapeutics (CATX) present at the Needham Virtual Healthcare Conference?

Perspective Therapeutics will present on April 14, 2026 from 9:30–10:10 a.m. ET; presentation includes a fireside chat. According to the company, the session is virtual and management will be available for questions during the scheduled presentation slot and follow-up investor outreach.

Is Perspective Therapeutics (CATX) available for one-on-one investor meetings at Piper Sandler Spring Biopharma Symposium?

Yes. Perspective Therapeutics will hold one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. According to the company, senior leadership will be available for scheduled 1x1s to discuss corporate strategy and pipeline updates with investors.

How can investors attend the Perspective Therapeutics (CATX) Needham presentation on April 14, 2026?

Investors can attend the Needham presentation virtually on April 14, 2026 at 9:30 a.m. ET via the conference platform. According to the company, the presentation and fireside chat are part of the virtual conference schedule and follow the event's access procedures.

What topics will Perspective Therapeutics (CATX) management likely cover at the April 2026 conferences?

Management is expected to discuss corporate strategy, radiopharmaceutical programs, and investor engagement plans during conference appearances. According to the company, senior leadership will use the Needham presentation and Piper Sandler 1x1s to update investors on program progress and strategic priorities.

Who from Perspective Therapeutics (CATX) will be available for investor meetings in April 2026?

Members of Perspective Therapeutics' senior leadership team will participate and be available for investor meetings at both events. According to the company, senior leaders will attend the Needham virtual presentation and hold one-on-one meetings at the Piper Sandler symposium.

Does Perspective Therapeutics (CATX) provide specific times for investor meetings at the Piper Sandler Spring Biopharma Symposium?

The company listed April 16, 2026 in Boston for one-on-one meetings but did not publish exact 1x1 times. According to the company, investors should follow Piper Sandler scheduling or contact management to arrange specific meeting slots during the symposium.